BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on ...

We recently published 10 Big Names Crushing Wall Street. BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the top-performing ...

The biotech’s phase 3 delivered the hoped-for second biomarker hit, reporting an 82% decline in serum creatine kinase after ...

Analysts estimate that BridgeBio Pharma will report an earnings per share (EPS) of $-0.82. The announcement from BridgeBio ...

The company intends to meet with the FDA to discuss results that showed a level of improvement on a marker of muscle ...

BridgeBio Pharma (BBIO) is scheduled to announce Q3 earnings results on Wednesday, October 29th, after market close. The consensus EPS Estimate is -$0.78 (+9.3% ...

BridgeBio Pharma said on Monday its experimental drug for a rare muscle disorder, which currently has no approved treatments, showed improvements in motor and lung function in a late-stage trial, ...

All primary and secondary interim analysis endpoints in FORTIFY Phase 3 study successfully achieved with well-tolerated safety profile ...

New interim data from a Phase III trial puts the company on track to file for FDA approval next year in an indication that ...

H.C. Wainwright raised the firm’s price target on BridgeBio (BBIO) to $80 from $70 and keeps a Buy rating on the shares. The firm now includes ...

BridgeBio Pharma Inc.’s drug to treat a devastating muscle-wasting disorder met its goal in a late-stage trial, paving the ...

BridgeBio Pharma shares surge on positive BBP-418 trial results for limb-girdle muscular dystrophy. Read more here.